Topic Archives: Migraine

Migraine Update

When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]

Comments

  • Avatar

    Could you tell me which CBD you use? I've been taking CBD for two years. I no longer suffer from severe migraine but it'...

  • Avatar

    Thank you for mentioning Aimovig, Ajovy, and Emgality, I never heard for them. I more into natural medicines. You should...

  • Avatar

    i started getting migraines at 40 terrible agonizing , paralyzing ! yes , the worst ones paralyze me on my left side...

  • Avatar

    FYI chronic migraine can change the symptom pattern of one sided pain to bilateral pain. I started experiencing exercis...

  • Avatar

    Michael, regarding the Vascular Hypothesis and imaging studies showing no increase in blood flow that one might expect f...

  • Avatar

    As a parent of a child who suffers from migraines to the extreme - passing out because of the pain... with the greatest ...

  • Avatar

    one of the stocks inthe Global Investing portfolio, Teva of Israel, expects to launch a migraine med based on deuterium ...

  • Gr8Full!

    #Private Kardium seeking CE Mark for breakthrough treatment of atrial fibrillation http://www.biotuesdays.com/features/...

  • Avatar

    Avanir Migraine Drug approval just announced - any insight / side effects / etc. that can be offered at this time...

  • Michael Jorrin,

    You might check the Doc Gumshoe piece about migraines - "More Than Just A bad Headache: Living With Migraines" - that po...

  • Gr8Full!

    #Migraine > https://www.fiercebiotech.com/biotech/lilly-buys-migraine-biotech-colucid-for-960m-and-drug-it-out-licensed...

  • Gr8Full!

    #EndPoints : TOP STORIES GlaxoSmithKline’s Hal Barron poaches Genentech’s top cancer drug dealmaker for his new R...

  • Gr8Full!

    Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest migraine...

  • Avatar

    Just wanted to add that while researching for the biotech company for the cancer vaccine I learned that Mangosteen juice...

  • Avatar

    $Ranitidine- I take RX strength dose daily for Barretts and have gotten Migraine type symptoms if I drink even small amo...

  • Avatar

    No ticker Couple of thoughts, if you don't mind... Your symptoms make sense as you are describing them, to a point. An...

  • Avatar

    I remember my neurologist mentioned that I don't fit the profile of someone with a migraine condition. Right-side pain a...

  • Dr. KSS MD PhD

    I have to say it's rather hard to tie all this together into a unifying process without examining you, particularly in t...

  • Avatar

    $Migraines $Magnesium I have been lucky enough to of never have had a simple headache in my life so far, but I would ...

  • Avatar

    One more thing, how do I know the symptoms were migraine prodrome? I attribute it to my experience with familiar symptom...

  • Dr. KSS MD PhD

    Are you male or female? Why do you use Flovent? what age are you? What other medications are you on? Have yo...

  • Avatar

    No ticker - I have a medical question that is unrelated to the stock discussion here. Over the last few months I experie...

  • Avatar

    $ AXSM NP Axsome Therapeutics announces AXS-07 for migraine treatment Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...

  • SoGiAm

    $AXSM Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine http://phx.corporate-ir.net/phoenix.zhtml?c=...

  • Avatar

    $AYTU Reverse split 3 out of 4 years. They passed the 2017 reverse split in 2016. Expect more. If you can understand th...

  • Avatar

    I KNOW FOR CERTAIN MAGNESIUM STOPPED MY MIGRAINES... BEEN FREE OF THEM FOR ABOUT 5 YRS NOW... HEADACHE DR. ADVICE SAID T...

  • Avatar

    the problem with drugs to deal with brain plaque to cure Alzheimer's is that we don't know if one causes the other, and ...

  • Avatar

    Migraine drug category getting crowded. https://endpts.com/tevas-cgrp-migraine-drug-aces-phiii-while-rivals-pile-up-at-...

  • Avatar

    Just wanted to share with Gummies a new stock I'm watching: $ZSAN - Zosano Pharma. Couldn't find this one on the Gummie ...

  • Avatar

    $CLCD $LLY $ACOR "The Long-term Effect of Acupuncture for Migraine Prophylaxis A Randomized Clinical Trial” (It w...

  • Avatar

    $CLCD, long Frenchy, I’m a little behind on the threads for the last few days, so I just saw your note on CoLucid. I ...

  • Avatar

    Weird you say that Helen, I am thinking about taking half of my position in CLCD which is up more than 350% in order to ...

  • Avatar

    I thought your comment on COQ10 having negative interactions with statins, beta blockers and anti-depressants quite inte...

  • Avatar

    $AMGN - Implications for $CLCD "Amgen's migraine drug succeeds in late-stage trial" (11/17) Nov 16 (Reuters) - Amg...

  • Avatar

    $CLCD (long) Follow-up on Newby 9/17 press release post: CoLucid Pharmaceuticals, Inc., a biopharmaceutical company ...

  • Avatar

    No position CLCD. I guess I'm luck, I don't know what a migraine feels like. And when I eat ice cream too fast, my thr...

  • Dr. KSS MD PhD

    Hi lingling: I wanted to reply to your recent post about migraines and lasmiditan from CoLucid. What we're seeing now...

  • Avatar

    $CLCD, $ALDR, #Migraine - $CLCD gained 14% today on raised target price by Piper Jaffray ($36 from $21) based on p...

  • Dr. KSS MD PhD

    My heartiest congratulations to all CoLucid longs....strong work! I sat this one out NOT because of any doubt but just f...

  • Dr. KSS MD PhD

    Lannas: it's hard, especially in the nonce, to leave big profits on the table. My honest opinion, FWIW, however, is that...

  • SoGiAm

    $CLCD long - Thanks ZKSS *CoLucid Pharmaceuticals +40% Premarket @$15.01; Co Announced Primary, Secondary Endpoints M...

  • SoGiAm

    $CLCD In - Week of Sept 5, 2016 sharing: http://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/comm...

  • Avatar

    For those looking to get in on $CLCD, remember to use limit bids and patience because data due out in two weeks or so. T...

  • Avatar

    We have a few trials due to give results in the coming weeks, so I figured I’d give Commandment #10 a try. First up is...

  • Avatar

    Very nice and useful article Doc, thanks so much. As far as what a SPA means here is a link that explains thoroughly wha...

  • Michael Jorrin (aka Doc Gumshoe)

    Thanks to all for the comments. To Griffin, sorry, but I don't know of any MDs or medical authorities in central Calif...

  • Avatar

    Doc Gumshoe, I suffer from what research I've done is food intolerance. The reason I've decided it is intolerance is t...

  • Avatar

    Dr. KSS, Thank you for the information about the tuning fork. In Jin Shin Jyutsu, a branch of Asian medicine, for a ...

  • Avatar

    To any migraine sufferers out there: For ten years, in my thirties, I had severe migraine headaches twice a month - eup...

  • Dr. KSS MD PhD

    Many chronic frontal headaches owe to mucus trapping in sinus air cells or pockets under pressure. For example, the baro...

  • Dr. KSS MD PhD

    The most important thing is not cardiac issues. It's that triptans just are not a very effective class of medicine. They...

  • Avatar

    I should have mentioned above the key point in my opinion is the high percentage of migraine sufferers who have cardio i...

  • Avatar

    Re CLCD , Dr. Lipton presents a strong case for the benefits of Lasmidistan for migraine sufferers with cardiovascular p...

  • Avatar

    CLCD stock price moved up a total of 50% in the 3 days after the meeting from about $6.20 to $9.60. Long CLCD and a m...

  • Avatar

    Regarding Colucid's strong positive movement last week which several asked about above, my take was that it was a result...

  • Avatar

    $CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...

  • Avatar

    $CLCD "CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Mi...

  • Avatar

    $TRVN In todays press release announcing that Trevena will present at the Jefferies 2016 Healthcare Conference, there...

  • Dr. KSS MD PhD

    I want to bring readers up to date on CoLucid ($CLCD), a biotech we floated as a long idea last year. CoLucid is phase 3...

  • Dr. KSS MD PhD

    Thanks a million diplacus: you caught me forgetting some of my own holdings. I promise readers I am not disorganized, bu...

  • SoGiAm

    $CELG - #Celgene highlights key #oncology data at #ASCO16 http://bit.ly/1TZRcCS $TGTX - "Majority of DLBCL responses...

  • JohnM

    I am long $ARLZ. I agree the Canadian drugs are me-too. They are deploying a new sales force this month to bring Fibric...

  • Dr. KSS MD PhD

    We've not peered in on Alder Bio in a while: it's announcing this am that its mAb against calcitonin gene-related peptid...

  • Dr. KSS MD PhD

    I may look at entering CLCD here. I have a sneaking feeling they may become a category killer in migraine the way Radius...

  • Dr. KSS MD PhD

    Yeah, totally nutso. Great company. Great drug....likely to become standard of care for migraine even if not first-line....

  • Avatar

    After this Biotech downturn some that look very enticing and undervalued to me that we follow at these prices with good...

  • Dr. KSS MD PhD

    To mthunder: Great queries and points. I say bravo to being in both $NK and $CLCD. They are both on my want list.....I h...

  • sogiam

    TRVN-Trevena Announces Presentations at PAINWeek(R) 2015 7:00 am ET September 8, 2015 (BusinessWire) Print Trevena, In...

  • sogiam

    TRVN-Trevena Appoints Yacoub Habib as Senior Vice President, Business Development and Corporate Planning KING OF PRUS...

  • Avatar

    Amgen's (AMGN) migraine drug report in a crowded field including our beloved CLCD which I hope is tops when it is all sa...

  • sogiam

    TRVN Long: Trevena Announces Poster Presentation of Data for Delta Receptor Compound TRV250 at American Headache Society...

  • Avatar

    Thanks Doc for explaing migraine headaches and what Trevena is chasing with its opioid receptor.You are awesome in expla...

  • Dr. KSS, MD PhD

    Glenn: this is in answer to your question from the other thread about Trevena's new delta opioid receptor biased ligand ...

  • Avatar

    Doc Kss, is Trevena (TRVN) chasing the same thing that CLCD is chasing with migraine's?If so I guess you would still con...

  • Dr. KSS, MD PhD

    I am still intensely skeptical: (1) other CGRP acting agents from other companies have failed (2) six months is stil...

  • Avatar

    $ALDR For Migraine sufferers (and investors): Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of...

  • sogiam

    TRVN-Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of b...

  • Avatar

    TRVN corporate update.Long TRVN. Trevena Reports First Quarter 2015 Financial Results and Provides a Corporate Update...

  • Dr. KSS, MD PhD

    No, I am not concerned. I don't want to sound callous, and I know migraine sufferers read here, and I have had a migrain...

  • Dr. KSS, MD PhD

    Mr Paglee....one thing to keep in mind is that CLCD said it was moving from Durham (a brain trust area) to Cambridge (an...

  • Dr. KSS, MD PhD

    Hey Dan: At least 2 other companies have had calcitonin gene related peptide-acting programs for migraine that have fail...

  • Avatar

    Any view on their migraine effort?...

  • Avatar

    CoLucid - Dr. KSS As a former chronic migraine sufferer, I read with great interest your excellent article regarding Co...

  • Avatar

    Thank you for the Special Bulletin on CLCD. I keep telling myself not to buy any more biotech without selling somethin...

  • Avatar

    Some food for thought... http://www.biocqr.com/#!/c1l55 Biggest Additions (more than 1 Million shares by at least tw...

  • Avatar

    In response to Doc Gumshoe's article, and to Dr. KSS who says that everything in it and the followup are 100% accurate, ...

  • Dr. KSS, MD PhD

    Avanir was a weird story. I don't think anyone dug their Nuedexta coughsyrup with a college education thing, and huge su...

  • Dr. KSS, MD PhD

    Ben/sogiam, anyone else interested in Alder ($ALDR). OK, I took a pretty thorough look here. For whatever reason Ben ...

  • sogiam

    FOR IMMEDIATE RELEASE Data from Phase 2b Clinical Trial of Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Trea...

  • Avatar

    Alder Biopharmaceuticals has gone from about $10 to $15.72 in a couple weeks. One of their drugs, ALD403, is a monoclon...

  • Avatar

    I've held Pozen for about 10 years, for a net of no gain. Their promise back then was the answer to Migraine headaches. ...

  • Avatar

    Re: # 734 [Frenchy] & # 739 [Jim T.] I believe the great Dr KSS is most assuridly a guy. Back @ 294 on 2-1, His po...

  • Avatar

    Good article on migraine by a neurologist migraine sufferer. Coffee, massage, yoga/meditation, and magnesium are reco...

  • Avatar

    Patricia...I know three people who had chronic migraines, all having the same experience you did. No more migraines aft...

  • Avatar

    Erm....happily speaking as one of the lucky 7% who cant remember the last time I got a headache, I saw this article rece...

  • Avatar

    I happen to be unpaid neurologist (unpaid because I volunteer at a free medical clinique ) I have some strong suggesti...

  • Avatar

    Dealing with migranes from the natural point of view (from naturalnews) Migraine sufferers are often anxious to rid t...

  • Avatar

    another very useful article on a drug need by Doc Gumshoe. Glaxo Smith Kline had a migraine drug that raised many hopes ...

  • Avatar

    Anyone suffering from Migraine? Saw this yesterday and thought of you. No pills just a magnet!!..not sure if its investa...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch